Walgreens shares rise after its earnings top estimates, fueled by higher drug sales

Earnings

People wear protective face masks outside Walgreens pharmacy in Union Square as the city continues Phase 4 of re-opening following restrictions imposed to slow the spread of coronavirus on September 24, 2020 in New York City.

Noam Galai | Getty Images

Walgreens Boots Alliance reported Thursday fiscal first-quarter earnings that exceeded Wall Street’s expectations, helped stronger-than-expected pharmacy sales.

Walgreens shares were up more than 4% in premarket trading.

Here’s what Walgreens reported compared with what analysts were expecting for the first quarter ended Nov. 30, based on Refinitiv data:

  • Earnings per share: $1.22 cents, adjusted vs. $1.03 expected
  • Revenue: $36.31 billion vs. $34.95 billion expected

In the first quarter, Walgreens posted net loss of $308 million, or 36 cents per share, compared with a net income of $845 million, or 95 cents per share, a year earlier.

Excluding a charge from its AmerisourceBergen investment, it earned $1.22 per share, higher than the $1.03 expected by analysts surveyed by Refinitiv.

Sales rose to $36.31 billion from $34.34 billion a year earlier, outpacing the $34.95 billion that analysts expected.

Walgreens has looked for growth opportunities as the drugstore industry faces disruption from e-commerce and heightened competition from other companies like Amazon, which recently entered the pharmacy business.

The pandemic has changed consumers’ patterns, too, as they cut back on trips to the store, opt for contactless options like curbside pickup and skip doctor’s appointments that can lead to new prescriptions.

Walgreens has responded by adding more health-care services to its stores and expanding its digital offerings. It unveiled a new mobile app and added curbside pickup at its U.S. stores, which can have online purchases ready for customers in as little as 30 minutes.

On Wednesday, it also announced it would sell its drug distribution business in Europe to U.S. drug wholesaler AmerisourceBergen for $6.5 billion. The sale will allow Walgreens to focus on its pharmacy and retail businesses, which have both taken a hit during the pandemic.

Walgreens started administering Covid vaccines in mid-December to staff and residents at nursing homes and other long-term care facilities. It plans to offer the shots to the general public at its drugstores, once they’re available.

Walgreens shares have fallen about 28% over the past one year, bring its market value to $37.2 billion.

Products You May Like

Articles You May Like

Coca-Cola and Pepsi won’t be advertising their namesake sodas during the Super Bowl
‘WandaVision’ debuts Friday, kicking off a new era for Marvel on Disney+
Biden unemployment plan: $400 weekly boost, extra benefits for six months
How to vet budgeting and investing apps before you hand over your information
Ether, the world’s second-biggest cryptocurrency, is closing in on an all-time high

Leave a Reply

Your email address will not be published. Required fields are marked *